Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclophosphamide added to lenalidomide and low-dose dexamethasone for biochemical progression in relapsed/refractory multiple myeloma
2012-000087-15Phase 2Active
- Sponsor
- Fondazione EMN Italy
- Start
- Apr 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cyclophosphamide, lenalidomide and dexamethasone in multiple myeloma (MM), sponsored by Fondazione EMN Italy. Primary endpoint: Primary efficacy. Started Apr 2012; status: active.
02
Drugs
cyclophosphamidelenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2012-000087-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-000087-15.